Headline
The lipid panel is the story this round. ApoB has climbed steadily across four panels — 0.78 in 2019, 0.84 in 2021, 0.94 in 2024, 1.12 now. LDL-C tracking with it. Total cholesterol and HDL holding stable, which means the carrier particles are doing more of the work. The other systems — kidneys, liver, metabolic, hormones — are largely where they should be.
What's changed since May 2024
ApoB +0.18 g/L. LDL-C +0.5 mmol/L. hsCRP doubled from 0.9 to 1.8. Triglycerides down from 1.1 to 0.8 — the Mediterranean diet pulling its weight there. Vitamin D up from 62 to 75, year-round Gold Coast sun showing up in the bloodwork. Magnesium up from 0.78 to 0.85 — supplement working.
What the panel can't see
Lipoprotein(a) — a one-time test for lifetime cardiovascular risk that isn't on this panel and probably should be. Coronary artery calcium score, if the GP suggests it. The diet detail that explains the saturated fat creep, if there's been one. Sleep architecture beyond duration.
The conversation with the GP
The headline question is whether the ApoB trajectory warrants intervention beyond diet and exercise. Some clinicians treat 1.12 with statins in a 51-year-old; others wait. A CAC scan answers that question concretely. Worth raising.